Prescription & Enrollment Form

Alpha-1

Policy#

Is patient eligible for Medicare? ☐ Yes ☐ No

Does patient have a secondary insurance? \square Yes \square No

Dispense as written

| - | | Date Date medication nee |
|---|--|---|
| Four simple steps to submit your referral. | 677 Ala Moana Blvd., Suite 404, Honolulu, HI 96813-5412 | Prescriber's first name Prescriber's last name |
| Constitution referrant | | Prescriber's title |
| 1 PATIENT INFORMATION | ☐ New patient ☐ Current | If NP or PA, under direction of Dr |
| | · · | Office contact and title |
| Patient's first name | | Office contact e-mail |
| Last name | | Clinic/hospital affiliation |
| Date of birth | ast 4 digits of SSN | Street address |
| Street address | Apt # | City State |
| City 9 | State Zip | Phone Fax |
| Parent/guardian (if applicable) | | NPI#License# |
| Home phone Work phone | Deliver product to: ☐ Office ☐ Patient's home ☐ Clinic | |
| Cell phone Evening phone | Clinic location | |
| E-mail address | | |
| Patient's primary language: English Other | | 3 CLINICAL INFORMATION |
| If other, please specify | | Primary ICD-10 code: ☐ E88.01 Alpha-1 antitrypsin deficiency |
| Please attach copies of front and back of patient s insurance | cards or complete information below. | Current weight □ Ib □ kg Date recorded |
| Insurance company | | Has the patient ever received augmentation therapy? ☐ Yes ☐ No |
| Insured's name | | If yes, which one: ☐ Aralast® ☐ Prolastin® ☐ Zemaira ☐ Glassia® |
| Insured's employer | | Smoking history: ☐ Yes ☐ No If yes, date stopped |
| Insured's employer | | □ NKDA □ Known drug allergies |
| Relationship to patient | - | Concurrent meds |
| Identification # Policy/g | roup # | Vascular access: ☐ Peripheral ☐ Central ☐ Port |
| Prescription card. Type TNo If yes carrier | | |

Group #

| 2 PRES | CRIBER INFORI | MATION | All fields must be completed to expedite prescription fulfillment. |
|--|----------------------------|---|--|
| Date | Time | Date medica | ation needed |
| | rst name | | |
| Prescriber's la | st name | | |
| Prescriber's tit | tle | | |
| If NP or PA, un | der direction of Dr | | |
| Office contact | t and title | | |
| Office contact | c e-mail | | |
| Clinic/hospita | l affiliation | | |
| | | | Suite # |
| | | | e Zip |
| Phone | | Fax | |
| NPI # | | License | :# |
| Deliver produc | ct to: ☐ Office ☐ Patien | nt's home 🚨 Clinic | С |
| Clinic location | I | | |
| Primary ICD-10 Current weight Has the patient If yes, which on Smoking histor NKDA | nown drug allergies eds | l antitrypsin deficie □ kg Date record ation therapy? □ Ye n® □ Zemaira □ G te stopped | ded es □ No Glassia® |
| Vascular acces | s: ☐ Peripheral ☐ Central | | |
| | Please attach/send th | ne following clinical | documentation: |

• PFTs

Substitution allowed

· Lung imaging

Non-smoker or smoking

(MD and patient signature)

cessation program attestation

• History and physical (signed)

Serum AAT with genotype

| Medication | Dose | Directions |
|--------------------------------------|---|---|
| ☐ Aralast-NP | ☐ Infuse 60mg per kg (+/−10%) intravenously weekly (where clinically | Infusion method: ☐ Gravity ☐ Pump |
| □ Glassia □ Zemaira | appropriate, round to the nearest vial size) ☐ Other regimen | Rate protocol: |
| - Zemana | - Other regimen | For Aralast-NP or Glassia: As tolerated by patient, not to exceed 0.2mL per kg per minute For Zemaira: As tolerated by patient, not to exceed 0.08mL per kg per minute |
| Premedication to | be given 30 minutes prior to infusion: 🚨 | |
| | be used as needed: (please strike through if not required) applied topically to insertion site prior to needle insertion as needed for intravenou | us site pain |
| Epinephrine 0.3n may repeat one t | | ster intramuscularly as needed for severe anaphylactic reaction times one dose; ularly as needed for severe anaphylactic reaction times one dose; may repeat one time. |
| Diphenhydramin | ne 25mg by mouth for mild allergic reactions and 50mg for moderate-severe. | |
| Flushing orders: | Normal saline 3mL intravenous (peripheral line) or 10mL intravenous (central line Heparin 10 units per mL 3mL intravenous (peripheral line) as final flush Heparin 100 units per mL 5mL intravenous (central line) as final flush | e) before and after infusion, or as needed for line patency |
| | e strike through if not required) ss, syringes, ancillary supplies and home medical equipment necessary to admini | ster medication. |
| Quantity/Refills | Dispense 1 month supply. Refill x 1 year unless noted otherwise. ☐ Dispense 90 day supply. Refill x 1 year unless noted otherwise. ☐ Other | |
| Lab Orders | | |
| Skilled nursing vi | isit as needed to establish venous access, administer medication and assess genera | al status and response to therapy. Visit frequency based on prescribed orders. |
| | oe required for therapy administration, the home health nurse will call for additional orders per state regulati cian's office, physician accepts on behalf of patient for administration in office. | ons. **ALL fields must be completed to expedite prescription fulfillment. |
| By signing below, | I certify that the above therapy is medically necessary. I also authorize Accrec | to to initiate any de minimus authorization processes from applicable health plans, if of prohibited. PHYSICIAN SIGNATURE REQUIRED |
| needed. including | the submission of any necessary forms to such health blans, to the extent no | of prohibited. DI IVCICIANI CICNIATI IDE DECLIIDED |

Please fax completed form to your drug therapy team at 808.650.6487. To reach your team, call toll-free 866.6ALPHA.1 or 808.650.6488. You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber

Date